Home >> Research Area >> Ceftiofur hydrochloride

Ceftiofur hydrochloride

CAS# 103980-44-5

Ceftiofur hydrochloride

Catalog No. BCC8911----Order now to get a substantial discount!

Product Name & Size Price Stock
Ceftiofur hydrochloride: 5mg $17 In Stock
Ceftiofur hydrochloride: 10mg Please Inquire In Stock
Ceftiofur hydrochloride: 20mg Please Inquire Please Inquire
Ceftiofur hydrochloride: 50mg Please Inquire Please Inquire
Ceftiofur hydrochloride: 100mg Please Inquire Please Inquire
Ceftiofur hydrochloride: 200mg Please Inquire Please Inquire
Ceftiofur hydrochloride: 500mg Please Inquire Please Inquire
Ceftiofur hydrochloride: 1000mg Please Inquire Please Inquire

Quality Control of Ceftiofur hydrochloride

Number of papers citing our products

Chemical structure

Ceftiofur hydrochloride

3D structure

Chemical Properties of Ceftiofur hydrochloride

Cas No. 103980-44-5 SDF Download SDF
PubChem ID 44828546 Appearance Powder
Formula C19H18ClN5O7S3 M.Wt 560
Type of Compound N/A Storage Desiccate at -20°C
Solubility >21.8mg/mL in DMSO
Chemical Name (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydron;chloride
SMILES [H+].CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O.[Cl-]
Standard InChIKey KEQFDTJEEQKVLM-JUODUXDSSA-N
Standard InChI InChI=1S/C19H17N5O7S3.ClH/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10;/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28);1H/b23-11-;/t12-,16-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Ceftiofur hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ceftiofur hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ceftiofur hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7857 mL 8.9286 mL 17.8571 mL 35.7143 mL 44.6429 mL
5 mM 0.3571 mL 1.7857 mL 3.5714 mL 7.1429 mL 8.9286 mL
10 mM 0.1786 mL 0.8929 mL 1.7857 mL 3.5714 mL 4.4643 mL
50 mM 0.0357 mL 0.1786 mL 0.3571 mL 0.7143 mL 0.8929 mL
100 mM 0.0179 mL 0.0893 mL 0.1786 mL 0.3571 mL 0.4464 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Ceftiofur hydrochloride

Negatively controlled, randomized clinical trial to evaluate use of intramammary ceftiofur for treatment of nonsevere culture-negative clinical mastitis.[Pubmed:30738678]

J Dairy Sci. 2019 Apr;102(4):3321-3338.

The objective of this negatively controlled randomized clinical trial was to compare clinical outcomes of 5-d intramammary treatment using Ceftiofur hydrochloride and no antimicrobial treatment of nonsevere culture-negative cases of clinical mastitis (CM). A total of 121 cases of nonsevere (abnormal milk or abnormal milk and udder) culture-negative CM were randomly assigned to either treatment (n = 62) or negative control (n = 59) groups. Quarters assigned to treatment received 1 daily intramammary infusion with an approved commercially available product containing Ceftiofur hydrochloride for 5 d. Quarters assigned to the negative control group did not receive any interventions. Enrolled cows were followed for 90 d or until the end of lactation. At enrollment, milk samples from the affected quarter were used for on-farm culture, somatic cell count (SCC) analysis, and further microbiological analysis. During the follow-up period, milk samples were collected for microbiological analysis and SCC analysis. No significant differences between treatment and negative control groups were identified for treatment failure (5% for treatment vs. 10% for negative control, n = 121), quarter-level CM recurrence (8 vs. 5%, n = 91), intramammary infection at 14 or 28 d after enrollment (13 vs. 26%, n = 86), days until clinical cure (4.2 vs. 4.0 d), days to culling (48.3 vs. 36.8 d), daily milk production (43.3 vs. 43.6 kg/cow per day), or weekly quarter SCC (5.5 vs. 5.4 log10 SCC). Days of milk discard were greater for cows assigned to the treatment group (8.5 d) compared with cows assigned to the negative control group (5.6 d). During the follow-up period, cases in the treatment group had a 50% risk reduction in IMI compared with cases in the negative control group. Irrespective of group, negative outcomes such as quarter-level CM recurrence (12%), treatment failure (12%), and culling (5%) occurred infrequently in nonsevere culture-negative cases of CM. Use of intramammary ceftiofur for treatment of nonsevere culture-negative cases of CM did not improve any economically relevant clinical outcome such as culling, milk production, or SCC.

In vitro antimicrobial activity against equine Lawsonia intracellularis strains.[Pubmed:30629755]

Equine Vet J. 2019 Jan 10.

BACKGROUND: Lawsonia intracellularis is the aetiologic agent of equine proliferative enteropathy (EPE). This emerging equine disease leads to diarrhoea, severe protein loss and can result in death if left untreated. Timely treatment of EPE is critical for recovery from the disease, and hence, information about antimicrobial susceptibilities of equine L. intracellularis strains to antimicrobials used in horses is needed. However, L. intracellularis is an obligate intracellular bacterium and so must be isolated and maintained in cell cultures. OBJECTIVES: To determine the in vitro antimicrobial activity of 14 antimicrobials against two equine L. intracellularis strains. STUDY DESIGN: In vitro experiments. METHODS: This study was designed to compare the relative in vitro susceptibility of each strain of L. intracellularis to different antimicrobials which included metronidazole, minocycline hydrochloride, erythromycin, cephalothin sodium salt, combination (4:1) of sulfamethazine and trimethoprim, chloramphenicol, rifampicin, penicillin, ampicillin, doxycycline hydrochloride, cefazolin sodium salt, clarithromycin, Ceftiofur hydrochloride and enrofloxacin. The minimum inhibitory concentration (MIC) was based on intracellular and extracellular activity that inhibited 99% of L. intracellularis growth in cell culture as compared to the antimicrobial-free control. RESULTS: Rifampicin and clarithromycin were the most active antimicrobials against the two L. intracellularis strains tested, with MICs of

Description

Ceftiofur hydrochloride is a semisynthetic antibiotic, with activity against various gram-positive and gram-negative, aerobic and anaerobic bacteria encountered by domestic animals.

Keywords:

Ceftiofur hydrochloride,103980-44-5,Natural Products, buy Ceftiofur hydrochloride , Ceftiofur hydrochloride supplier , purchase Ceftiofur hydrochloride , Ceftiofur hydrochloride cost , Ceftiofur hydrochloride manufacturer , order Ceftiofur hydrochloride , high purity Ceftiofur hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: